Stefano Fiorucci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9008136/publications.pdf

Version: 2024-02-01

248	16,061	16451 64	20358 116
papers	citations	h-index	g-index

254	254	254	15329
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Linking liver metabolic and vascular disease via bile acid signaling. Trends in Molecular Medicine, 2022, 28, 51-66.	6.7	16
2	Organoids as ex vivo culture system to investigate infection-host interaction in gastric pre-carcinogenesis.. Recent Advances in Inflammation & Allergy Drug Discovery, 2022, 16, .	0.8	4
3	Discovery of Bile Acid Derivatives as Potent ACE2 Activators by Virtual Screening and Essential Dynamics. Journal of Chemical Information and Modeling, 2022, 62, 196-209.	5.4	15
4	GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation. Cells, 2022, 11, 1187.	4.1	9
5	Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. FASEB Journal, 2022, 36, e22060.	0.5	9
6	Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease. Frontiers in Pharmacology, 2022, 13, 858137.	3.5	4
7	Immunomodulatory functions of FXR. Molecular and Cellular Endocrinology, 2022, 551, 111650.	3.2	22
8	Bile Acid Signaling in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, 66, 674-693.	2.3	102
9	Special FX: Harnessing the Farnesoid-X-Receptor to Control Bile Acid Synthesis. Digestive Diseases and Sciences, 2021, 66, 3668-3671.	2.3	5
10	Bile acids and their receptors in metabolic disorders. Progress in Lipid Research, 2021, 82, 101094.	11.6	112
11	The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. Expert Opinion on Drug Discovery, 2021, 16, 1193-1208.	5.0	17
12	Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential. Frontiers in Oncology, 2021, 11, 663771.	2.8	15
13	Bile Acids Activated Receptors in Inflammatory Bowel Disease. Cells, 2021, 10, 1281.	4.1	39
14	Inverse Virtual Screening for the rapid re-evaluation of the presumed biological safe profile of natural products. The case of steviol from Stevia rebaudiana glycosides on farnesoid X receptor (FXR). Bioorganic Chemistry, 2021, 111, 104897.	4.1	3
15	Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction. Biochemical Pharmacology, 2021, 188, 114564.	4.4	18
16	Bile acid metabolism and bile acid receptor signaling in metabolic diseases and therapy. Liver Research, 2021, 5, 103-104.	1.4	4
17	Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease. Liver Research, 2021, 5, 119-141.	1.4	15
18	The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy. FASEB Journal, 2021, 35, e21271.	0.5	15

#	Article	IF	Citations
19	Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1. Journal of Medicinal Chemistry, 2021, 64, 16512-16529.	6.4	3
20	Variability in Probiotic Formulations Revealed by Proteomics and Physico-chemistry Approach in Relation to the Gut Permeability. Probiotics and Antimicrobial Proteins, 2020, 12, 1193-1202.	3.9	10
21	Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. Frontiers in Chemistry, 2020, 8, 572885.	3.6	76
22	Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders. Current Opinion in Pharmacology, 2020, 53, 45-54.	3.5	33
23	Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1. Biochemical Pharmacology, 2020, 177, 113987.	4.4	5
24	Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opinion on Investigational Drugs, 2020, 29, 623-632.	4.1	67
25	The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity. Journal of Immunology, 2020, 204, 2535-2551.	0.8	24
26	GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis. ACS Medicinal Chemistry Letters, 2020, 11, 818-824.	2.8	8
27	Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation. Nutrients, 2020, 12, 1945.	4.1	10
28	Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158733.	2.4	22
29	The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions. Nutrients, 2019, 11, 1820.	4.1	25
30	Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 1422-1437.	2.4	37
31	GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 447-473.	4.5	37
32	Chenodeoxycholic Acid: An Update on Its Therapeutic Applications. Handbook of Experimental Pharmacology, 2019, 256, 265-282.	1.8	41
33	Mo2014 â€“ Comparative Effects of Bar502, a Dual Fxr and Gpbar1 Agonist, Obeticholic Acid and Ursodeoxycholic Acid in a Rodent Model of Nash. Gastroenterology, 2019, 156, S-925-S-926.	1.3	1
34	Tu1546 â€“ Gpbar1 is a Modulator of Liver Immunity and Its Agonism Reverses Acetaminophen-Induced Hepatotoxicity by Modulating Recruitment of Liver Macrophages. Gastroenterology, 2019, 156, S-1052.	1.3	0
35	Sa1518 â€“ Mechanism of Acute Liver Decompensation Caused by Obeticholic Acid in Cholestasis is Fxr Dependent. Gastroenterology, 2019, 156, S-1231.	1.3	0
36	Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties. Nutrients, 2019, 11, 325.	4.1	32

#	Article	IF	Citations
37	Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. Nutrients, 2019, 11, 1132.	4.1	21
38	Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. Handbook of Experimental Pharmacology, 2019, 256, 283-295.	1.8	55
39	The Pharmacology of Bile Acids and Their Receptors. Handbook of Experimental Pharmacology, 2019, 256, 3-18.	1.8	79
40	Serum Bile Acid Levels Before and After Sleeve Gastrectomy and Their Correlation with Obesity-Related Comorbidities. Obesity Surgery, 2019, 29, 2517-2526.	2.1	17
41	Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties. Molecules, 2019, 24, 1043.	3.8	3
42	Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1. Scientific Reports, 2019, 9, 2504.	3.3	13
43	Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists. ACS Medicinal Chemistry Letters, 2019, 10, 504-510.	2.8	27
44	Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite. Chemosphere, 2019, 215, 870-880.	8.2	31
45	Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury. ACS Medicinal Chemistry Letters, 2019, 10, 407-412.	2.8	27
46	Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. FASEB Journal, 2019, 33, 2809-2822.	0.5	40
47	Farnesoid X receptor modulators 2014-present: a patent review. Expert Opinion on Therapeutic Patents, 2018, 28, 351-364.	5.0	72
48	Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2018, 24, 123-135.	1.9	12
49	Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2018, 63, 2168-2171.	2.3	2
50	Disruption of TFGÎ²-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand. Pharmacological Research, 2018, 131, 17-31.	7.1	25
51	Amphiphilic polypeptides with prolonged enzymatic stability for the preparation of self-assembled nanobiomaterials. RSC Advances, 2018, 8, 34603-34613.	3.6	15
52	Synthesis and characterization of well-defined poly(2-deoxy-2-methacrylamido-d-glucose) and its biopotential block copolymers via RAFT and ROP polymerization. European Polymer Journal, 2018, 105, 26-37.	5.4	19
53	241 - GPBAR1 (TGR5) is a Modulator of Liver Immunity and Reverses Liver Inflammation in a Mouse Models of Acute Hepatitis. Gastroenterology, 2018, 154, S-1078.	1.3	0
54	Tu1738 - The Aryl Hydrocarbon Receptor Mediates Anti-Inflammatory Activities of Natural and Synthetic Pelargonidines in Mouse Models of Colitis. Gastroenterology, 2018, 154, S-1006.	1.3	0

#	Article	IF	Citations
55	2 - GPBAR1 (TGR5) Agonism Reverses Endothelial Dysfunction and Liver Injury in a Dietetic Model of Steatohepatitis. Gastroenterology, 2018, 154, S-1.	1.3	0
56	Bile Acids Activated Receptors Regulate Innate Immunity. Frontiers in Immunology, 2018, 9, 1853.	4.8	334
57	Tu1748 - Probiotics Beyond Taxonomy: Evidence that Anti-inflammatory Properties of Live Biotherapeutic Products Require Phenotypic Characterization. Gastroenterology, 2018, 154, S-1008-S-1009.	1.3	0
58	Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacological Research, 2018, 134, 289-298.	7.1	54
59	Su1053 - Bar704, a Potent and Selective Fxr Agonist Protects Against Intestinal Fibrosis. Gastroenterology, 2018, 154, S-469.	1.3	1
60	Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 312, H21-H32.	3.2	38
61	Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis. Scientific Reports, 2017, 7, 41055.	3.3	12
62	BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Scientific Reports, 2017, 7, 42801.	3.3	94
63	Hyodeoxycholic acid derivatives as liver X receptor Î± and G-protein-coupled bile acid receptor agonists. Scientific Reports, 2017, 7, 43290.	3.3	30
64	BAR130, a Hyodeoxycholic Acid Derivative as the First Example of Dual LXRÎ±/GPBAR1 Agonist. Gastroenterology, 2017, 152, S634.	1.3	0
65	Variability in Industrial Production Affects Probiotics Activity: Identification of Batches of Probiotic VSL#3 that Increases Intestinal Permeability and Worsens Colitis in Rodents. Gastroenterology, 2017, 152, S969.	1.3	2
66	BAR501, A Selective Gpbar1 Agonist, Promotes Adipose Tissue Browning and Autophagy and Improves Lipid Metabolism and Steato-Hepatitis in Mice Feed a High Fat Diet. Gastroenterology, 2017, 152, S683.	1.3	0
67	Discovery of Bar704, A Potent and Selective FXR Agonist, that Protects Against Liver Fibrosis. Gastroenterology, 2017, 152, S300-S301.	1.3	0
68	GPBAR1 (TGR5) Ligation Protects Against Colitis Development by Regulating Leukocyte Traffinking and Promoting a IL-10 Dependent Shift in the M1/M2 Phenotype. Gastroenterology, 2017, 152, S135.	1.3	1
69	The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. Journal of Immunology, 2017, 199, 718-733.	0.8	198
70	Gpbar1 agonism promotes a Pgc-1Î±-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice. Scientific Reports, 2017, 7, 13689.	3.3	36
71	Epoxide functionalization on cholane side chains in the identification of G-protein coupled bile acid receptor (GPBAR1) selective agonists. RSC Advances, 2017, 7, 32877-32885.	3.6	4
72	Nanotraps with biomimetic surface as decoys for chemokines. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2575-2585.	3.3	14

#	Article	IF	Citations
73	Bisphenol AF: Does bisphenol AF glucuronide have endocrine activity?. Toxicology Letters, 2017, 280, S111.	0.8	0
74	Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases. Frontiers in Pharmacology, 2017, 8, 162.	3.5	23
75	Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity. Frontiers in Pharmacology, 2017, 8, 505.	3.5	49
76	Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World Journal of Gastroenterology, 2016, 22, 2219-2241.	3.3	249
77	Phallusiasterol C, A New Disulfated Steroid from the Mediterranean Tunicate Phallusia fumigata. Marine Drugs, 2016, 14, 117.	4.6	7
78	Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists. Scientific Reports, 2016, 6, 19008.	3.3	38
79	Sa1587 A Comprehensive Analysis of Small Heterodimer Partner (SHP) Target Genes in Hepatic Stellate Cells and the Discovery of a New Class of SHP Agonists That Reduces Liver Fibrosis. Gastroenterology, 2016, 150, S335.	1.3	0
80	825 BAR502, a Dual FXR and GPBAR1 Agonist, Reverses Steatosis and Fibrosis in Rodent Model of NASH By Modulating Authophagic Genes. Gastroenterology, 2016, 150, S173.	1.3	1
81	Mo1915 Genetic Ablation and Pharmacological Blockade of CCR5 by the anti-HIV Small Molecule Inhibitor Maraviroc Inhibits Leukocyte Trafficking and Protects Against Mucosal Inflammation in Murine Models Colitis. Gastroenterology, 2016, 150, S815.	1.3	0
82	Targeting the transsulfuration-H 2 S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension. Pharmacological Research, 2016, 111, 749-756.	7.1	14
83	Receptor-ligand interactions: Advanced biomedical applications. Materials Science and Engineering C, 2016, 68, 890-903.	7.3	46
84	New brominated flame retardants and their metabolites as activators of the pregnane X receptor. Toxicology Letters, 2016, 259, 116-123.	0.8	12
85	Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Scientific Reports, 2016, 6, 30802.	3.3	48
86	Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands. Scientific Reports, 2016, 6, 29320.	3.3	13
87	Tu1828 GPBAR1(TGR5) Is Highly Expressed in Human Gastric Cancers and Its Activation by Selective or GPBAR1/FXR Dual Ligands Promotes Epithelial Mesenchymal Transition and Tumor Spreading. Gastroenterology, 2016, 150, S955.	1.3	0
88	Mo1916 BAR 501, a Novel GPBAR1 Ligand, Reverses Intestinal and Liver Inflammatory Models Demonstrating That GPBAR1 Is an Essential Modulator of Innate Immunity in Entero-Hepatic Tissues. Gastroenterology, 2016, 150, S815.	1.3	0
89	Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity. Steroids, 2016, 105, 59-67.	1.8	16
90	The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget, 2016, 7, 61021-61035.	1.8	44

#	Article	IF	Citations
91	Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism. Scientific Reports, 2015, 5, 16605.	3.3	23
92	The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma. Scientific Reports, 2015, 5, 15403.	3.3	6
93	Inhibition of Chronic Ulcerative Colitis-associated Adenocarcinoma Development in Mice by VSL#3. Inflammatory Bowel Diseases, 2015, 21, 1027-1037.	1.9	53
94	Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling. PLoS ONE, 2015, 10, e0129866.	2.5	43
95	Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa. Journal of Gastroenterology, 2015, 50, 707-719.	5.1	23
96	Farnesoid X receptor modulators (2011 â€“ 2014): a patent review. Expert Opinion on Therapeutic Patents, 2015, 25, 885-896.	5.0	23
97	Interactions Between Nuclear Receptor SHP and FOXA1 Maintain Oscillatory Homocysteine Homeostasis in Mice. Gastroenterology, 2015, 148, 1012-1023.e14.	1.3	43
98	Cystathionine Î³-lyase, a H₂S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H114-H126.	3.2	45
99	Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. Trends in Molecular Medicine, 2015, 21, 702-714.	6.7	368
100	Diethylstilbestrol-scaffold-based pregnane X receptor modulators. European Journal of Medicinal Chemistry, 2015, 103, 551-562.	5.5	6
101	Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application. Future Medicinal Chemistry, 2015, 7, 1109-1135.	2.3	32
102	Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS ONE, 2015, 10, e0141082.	2.5	51
103	The HIV Matrix Protein p17 Promotes the Activation of Human Hepatic Stellate Cells through Interactions with CXCR2 and Syndecan-2. PLoS ONE, 2014, 9, e94798.	2.5	8
104	Solomonsterol A, a Marine Pregnane-X-Receptor Agonist, Attenuates Inflammation and Immune Dysfunction in a Mouse Model of Arthritis. Marine Drugs, 2014, 12, 36-53.	4.6	25
105	Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP. PLoS ONE, 2014, 9, e106503.	2.5	175
106	Bazedoxifene-Scaffold-Based Mimetics of Solomonsterols A and B as Novel Pregnane X Receptor Antagonists. Journal of Medicinal Chemistry, 2014, 57, 4819-4833.	6.4	18
107	Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands. Journal of Medicinal Chemistry, 2014, 57, 8477-8495.	6.4	76
108	Modification on Ursodeoxycholic Acid (UDCA) Scaffold. Discovery of Bile Acid Derivatives As Selective Agonists of Cell-Surface G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1). Journal of Medicinal Chemistry, 2014, 57, 7687-7701.	6.4	62

#	Article	IF	Citations
109	Design, Synthesis, and Biological Evaluation of Potent Dual Agonists of Nuclear and Membrane Bile Acid Receptors. Journal of Medicinal Chemistry, 2014, 57, 937-954.	6.4	79
110	Insights on pregnane-X-receptor modulation. Natural and semisynthetic steroids from Theonella marine sponges. European Journal of Medicinal Chemistry, 2014, 73, 126-134.	5.5	14
111	Incisterols, highly degraded marine sterols, are a new chemotype of PXR agonists. Steroids, 2014, 83, 80-85.	1.8	14
112	Marine and Semi-Synthetic Hydroxysteroids as New Scaffolds for Pregnane X Receptor Modulation. Marine Drugs, 2014, 12, 3091-3115.	4.6	13
113	Phallusiasterols A and B: Two New Sulfated Sterols from the Mediterranean Tunicate Phallusia fumigata and Their Effects as Modulators of the PXR Receptor. Marine Drugs, 2014, 12, 2066-2078.	4.6	17
114	Targeting FXR in cholestasis: hype or hope. Expert Opinion on Therapeutic Targets, 2014, 18, 1449-59.	3.4	37
115	Dissociation of Intestinal and Hepatic Activities of FXR and LXRÎ± Supports Metabolic Effects of Terminal Ileum Interposition in Rodents. Diabetes, 2013, 62, 3384-3393.	0.6	51
116	Isoswinholide B and swinholide K, potently cytotoxic dimeric macrolides from Theonella swinhoei. Bioorganic and Medicinal Chemistry, 2013, 21, 5332-5338.	3.0	17
117	Binding Mechanism of the Farnesoid X Receptor Marine Antagonist Suvanine Reveals a Strategy To Forestall Drug Modulation on Nuclear Receptors. Design, Synthesis, and Biological Evaluation of Novel Ligands. Journal of Medicinal Chemistry, 2013, 56, 4701-4717.	6.4	49
118	CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. Translational Oncology, 2013, 6, 784-793.	3.7	47
119	FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. Pharmacological Research, 2013, 77, 1-10.	7.1	14
120	Epigenetic Modulation by Methionine Deficiency Attenuates the Potential for Gastric Cancer Cell Dissemination. Journal of Gastrointestinal Surgery, 2013, 17, 39-49.	1.7	14
121	Activation of the bile acid receptor <scp>GPBAR</scp>1 protects against gastrointestinal injury caused by nonâ€steroidal antiâ€inflammatory drugs and aspirin in mice. British Journal of Pharmacology, 2013, 168, 225-237.	5.4	17
122	Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice. Circulation, 2013, 127, 2114-2124.	1.6	114
123	Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome. PLoS ONE, 2013, 8, e63893.	2.5	89
124	New tridecapeptides of the theonellapeptolide family from the Indonesian sponge Theonella swinhoei. Beilstein Journal of Organic Chemistry, 2013, 9, 1643-1651.	2.2	10
125	Oxygenated Polyketides from Plakinastrella mamillaris as a New Chemotype of PXR Agonists. Marine Drugs, 2013, 11, 2314-2327.	4.6	41
126	The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation. PLoS ONE, 2013, 8, e54472.	2.5	82

#	Article	IF	Citations
127	Preliminary Structure-Activity Relationship on Theonellasterol, a New Chemotype of FXR Antagonist, from the Marine Sponge Theonella swinhoei. Marine Drugs, 2012, 10, 2448-2466.	4.6	17
128	Development of FXR, PXR and CAR Agonists and Antagonists for Treatment of Liver Disorders. Current Topics in Medicinal Chemistry, 2012, 12, 605-624.	2.1	36
129	Editorial [Hot Topic :Current Advances In Therapeutic Applications of Nuclear Receptors (Guest) Tj ETQq1 1 0.784314 rgBT /Overlock	2.1	1
130	Quantitative NMR-Derived Interproton Distances Combined with Quantum Mechanical Calculations of ¹³C Chemical Shifts in the Stereochemical Determination of Conicasterol F, a Nuclear Receptor Ligand from Theonella swinhoei. Journal of Organic Chemistry, 2012, 77, 1489-1496.	3.2	81
131	Marine sponge steroids as nuclear receptor ligands. Trends in Pharmacological Sciences, 2012, 33, 591-601.	8.7	47
132	Modification in the side chain of solomonsterol A: discovery of cholestan disulfate as a potent pregnane-X-receptor agonist. Organic and Biomolecular Chemistry, 2012, 10, 6350.	2.8	20
133	Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide C. Molecular BioSystems, 2012, 8, 1412.	2.9	10
134	Conicasterol E, a Small Heterodimer Partner Sparing Farnesoid X Receptor Modulator Endowed with a Pregnane X Receptor Agonistic Activity, from the Marine Sponge Theonella swinhoei. Journal of Medicinal Chemistry, 2012, 55, 84-93.	6.4	43
135	4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. Steroids, 2012, 77, 484-495.	1.8	40
136	Chalinulasterol, a Chlorinated Steroid Disulfate from the Caribbean Sponge Chalinula molitba. Evaluation of Its Role as PXR Receptor Modulator. Marine Drugs, 2012, 10, 1383-1390.	4.6	14
137	Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Medicinal Chemistry, 2012, 4, 877-891.	2.3	42
138	Plakilactones from the Marine Sponge Plakinastrella mamillaris. Discovery of a New Class of Marine Ligands of Peroxisome Proliferator-Activated Receptor Î³. Journal of Medicinal Chemistry, 2012, 55, 8303-8317.	6.4	47
139	Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis. PLoS ONE, 2012, 7, e30443.	2.5	62
140	Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB Journal, 2012, 26, 3021-3031.	0.5	48
141	Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-Î³-dependent manner. Antiviral Therapy, 2012, 17, 669-678.	1.0	16
142	The First Total Synthesis of Solomonsterol B, a Marine Pregnane X Receptor Agonist. European Journal of Organic Chemistry, 2012, 2012, 5187-5194.	2.4	17
143	The HIV Matrix Protein p17 Subverts Nuclear Receptors Expression and Induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes. PLoS ONE, 2012, 7, e35924.	2.5	25
144	VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. PLoS ONE, 2012, 7, e45425.	2.5	90

#	Article	IF	Citations
145	Gene expression changes induced by HIPEC in a murine model of gastric cancer. In Vivo, 2012, 26, 39-45.	1.3	8
146	Theonellasterols and Conicasterols fromTheonella swinhoei. Novel Marine Natural Ligands for Human Nuclear Receptors. Journal of Medicinal Chemistry, 2011, 54, 3065-3075.	6.4	61
147	Total Synthesis and Pharmacological Characterization of Solomonsterol A, a Potent Marine Pregnane-X-Receptor Agonist Endowed with Anti-Inflammatory Activity. Journal of Medicinal Chemistry, 2011, 54, 4590-4599.	6.4	53
148	Probiotics Modulate Intestinal Expression of Nuclear Receptor and Provide Counter-Regulatory Signals to Inflammation-Driven Adipose Tissue Activation. PLoS ONE, 2011, 6, e22978.	2.5	83
149	Solomonsterols A and B fromTheonella swinhoei. The First Example of C-24 and C-23 Sulfated Sterols from a Marine Source Endowed with a PXR Agonistic Activity. Journal of Medicinal Chemistry, 2011, 54, 401-405.	6.4	51
150	Discovery of Sulfated Sterols from Marine Invertebrates as a New Class of Marine Natural Antagonists of Farnesoid-X-Receptor. Journal of Medicinal Chemistry, 2011, 54, 1314-1320.	6.4	59
151	Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2011, 1809, 157-165.	1.9	59
152	Towards new ligands of nuclear receptors. Discovery of malaitasterol A, an unique bis-secosterol from marine sponge Theonella swinhoei. Organic and Biomolecular Chemistry, 2011, 9, 4856.	2.8	35
153	The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis. PLoS ONE, 2011, 6, e25637.	2.5	297
154	Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. British Journal of Pharmacology, 2011, 164, 1929-1938.	5.4	32
155	Inhibition of NF-Î°B by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. European Journal of Pharmacology, 2011, 668, 317-324.	3.5	97
156	SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-Î³ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. Inflammation Research, 2011, 60, 577-587.	4.0	42
157	Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment. Current Medicinal Chemistry, 2010, 17, 139-159.	2.4	59
158	Hydrogen Sulphide Induces Î¼ Opioid Receptor-Dependent Analgesia in a Rodent Model of Visceral Pain. Molecular Pain, 2010, 6, 1744-8069-6-36.	2.1	40
159	Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochemical Pharmacology, 2010, 80, 1700-1707.	4.4	86
160	FXR an emerging therapeutic target for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine, 2010, 14, 79-92.	3.6	66
161	The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice. PLoS ONE, 2010, 5, e13238.	2.5	28
162	FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Journal of Lipid Research, 2010, 51, 771-784.	4.2	363

#	Article	IF	Citations
163	The bile acid sensor FXR regulates insulin transcription and secretion. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 363-372.	3.8	153
164	Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Progress in Lipid Research, 2010, 49, 171-185.	11.6	121
165	The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity. Journal of Immunology, 2009, 183, 6251-6261.	0.8	485
166	The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis. Journal of Immunology, 2009, 183, 6657-6666.	0.8	134
167	Antiatherosclerotic effect of farnesoid X receptor. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H272-H281.	3.2	166
168	The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. Biochemical Pharmacology, 2009, 78, 1214-1223.	4.4	74
169	Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends in Pharmacological Sciences, 2009, 30, 570-580.	8.7	295
170	A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. Pharmacological Research, 2009, 59, 319-329.	7.1	14
171	Farnesoid X receptor agonists in biliary tract disease. Current Opinion in Gastroenterology, 2009, 25, 252-259.	2.3	52
172	Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World Journal of Gastroenterology, 2009, 15, 2097.	3.3	54
173	The methionine connection: Homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. Hepatology, 2008, 47, 659-667.	7.3	63
174	Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anti-Cancer Drugs, 2007, 18, 1081-1091.	1.4	28
175	Targeting farnesoid X receptor for liver and metabolic disorders. Trends in Molecular Medicine, 2007, 13, 298-309.	6.7	179
176	A Hydrogenâ€Sulfide Releasing Derivative of Mesalamine Exhibits Markedly Enhanced Antiâ€Inflammatory Effects in Experimental Colitis. FASEB Journal, 2007, 21, A131.	0.5	0
177	Back Door Modulation of the Farnesoid X Receptor:Â Design, Synthesis, and Biological Evaluation of a Series of Side Chain Modified Chenodeoxycholic Acid Derivatives. Journal of Medicinal Chemistry, 2006, 49, 4208-4215.	6.4	46
178	The Emerging Roles of Hydrogen Sulfide in the Gastrointestinal Tract and Liver. Gastroenterology, 2006, 131, 259-271.	1.3	343
179	5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 447-458.	2.5	130
180	PPARs and other nuclear receptors in inflammation. Current Opinion in Pharmacology, 2006, 6, 421-427.	3.5	119

#	Article	IF	Citations
181	Unveiling hidden features of orphan nuclear receptors: The case of the small heterodimer partner (SHP). Journal of Molecular Graphics and Modelling, 2006, 24, 362-372.	2.4	25
182	3Î±-6Î±-Dihydroxy-7Î±-fluoro-5Î²-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17Î±-ethynyl-estradiol-induced cholestasis in rats. Toxicology and Applied Pharmacology, 2006, 214, 199-208.	2.8	6
183	Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NOâ€pegylated epirubicin. FASEB Journal, 2006, 20, 765-767.	0.5	47
184	Evidence That Hydrogen Sulfide Exerts Antinociceptive Effects in the Gastrointestinal Tract by Activating KATP Channels. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 325-335.	2.5	238
185	Essential requirement for sphingosine kinase activity in eNOSâ€dependent NO release and vasorelaxation. FASEB Journal, 2006, 20, 340-342.	0.5	36
186	Hydrogen sulfide is an endogenous modulator of leukocyteâ€mediated inflammation. FASEB Journal, 2006, 20, 2118-2120.	0.5	765
187	The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo. Molecular Pharmacology, 2006, 70, 1164-1173.	2.3	145
188	Disruption of an SP2/KLF6 Repression Complex by SHP Is Required for Farnesoid X Receptor-induced Endothelial Cell Migration. Journal of Biological Chemistry, 2006, 281, 39105-39113.	3.4	69
189	A role for proteinase-activated receptor-1 in inflammatory bowel diseases. Journal of Clinical Investigation, 2006, 116, 2056-2056.	8.2	5
190	Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor Î³ Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 58-68.	2.5	169
191	Proteinase-activated Receptor-1 is an Anti-Inflammatory Signal for Colitis Mediated by a Type 2 Immune Response. Inflammatory Bowel Diseases, 2005, 11, 792-798.	1.9	56
192	The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology, 2005, 42, 539-548.	7.3	504
193	Dual COX-Inhibitors: The Answer is NO?. Current Topics in Medicinal Chemistry, 2005, 5, 487-492.	2.1	8
194	A Farnesoid X Receptor-Small Heterodimer Partner Regulatory Cascade Modulates Tissue Metalloproteinase Inhibitor-1 and Matrix Metalloprotease Expression in Hepatic Stellate Cells and Promotes Resolution of Liver Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 584-595.	2.5	176
195	The Methyl Transferase PRMT1 Functions as Co-Activator of Farnesoid X Receptor (FXR)/9-cis Retinoid X Receptor and Regulates Transcription of FXR Responsive Genes. Molecular Pharmacology, 2005, 68, 551-558.	2.3	74
196	Proteinase-Activated Receptor-2 Mediates Arterial Vasodilation in Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2349-2354.	2.4	36
197	Role of FXR in Regulating Bile Acid Homeostasis and Relevance for Human Diseases. Current Drug Targets Immune, Endocrine and Metabolic Disorders, 2005, 5, 289-303.	1.8	96
198	Farnesoid X Receptor:Â From Structure to Potential Clinical Applications. Journal of Medicinal Chemistry, 2005, 48, 5383-5403.	6.4	125

#	Article	IF	Citations
199	Protective Effects of 6-Ethyl Chenodeoxycholic Acid, a Farnesoid X Receptor Ligand, in Estrogen-Induced Cholestasis. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 604-612.	2.5	190
200	Enhanced Anti-Inflammatory Potency of a Nitric Oxide-Releasing Derivative of Flunisolide: Role of Nuclear Factor-Î²B. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1096-1102.	2.5	18
201	Nitric Oxide (NO)-Releasing Naproxen (HCT-3012 [(S)-6-Methoxy-Î±-methyl-2-naphthaleneacetic Acid) Tj ETQq1 1 0.784314 rgBT /Overlo for Aspirin-Triggered Lipoxin, Prostaglandins, and NO in Gastric Protection. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 1264-1271.	2.5	26
202	Aspirin-Triggered, Cyclooxygenase-2â€“Dependent Lipoxin Synthesis Modulates Vascular Tone. Circulation, 2004, 110, 1320-1325.	1.6	51
203	Cooperation between Aspirin-Triggered Lipoxin and Nitric Oxide (NO) Mediates Antiadhesive Properties of 2-(Acetyloxy)benzoic Acid 3-(Nitrooxymethyl)phenyl Ester (NCX-4016) (NO-Aspirin) on Neutrophil-Endothelial Cell Adherence. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1174-1182.	2.5	42
204	Diabetic Mouse Angiopathy Is Linked to Progressive Sympathetic Receptor Deletion Coupled to an Enhanced Caveolin-1 Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 721-726.	2.4	55
205	Nitric Oxide Regulates Immune Cell Bioenergetic: A Mechanism to Understand Immunomodulatory Functions of Nitric Oxide-Releasing Anti-Inflammatory Drugs. Journal of Immunology, 2004, 173, 874-882.	0.8	33
206	A Â-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15736-15741.	7.1	148
207	PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology, 2004, 39, 365-375.	7.3	149
208	The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology, 2004, 127, 1497-1512.	1.3	406
209	Co-Administration of Nitric Oxide-Aspirin (NCX-4016) and Aspirin Prevents Platelet and Monocyte Activation and Protects Against Gastric Damage Induced by Aspirin in Humans. Journal of the American College of Cardiology, 2004, 44, 635-641.	2.8	45
210	Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structureâ^'Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid. Journal of Medicinal Chemistry, 2004, 47, 4559-4569.	6.4	166
211	Treatment of Portal Hypertension with NCXâ€1000, a Liverâ€Specific NO donor. A Review of Its Current Status. Cardiovascular Drug Reviews, 2004, 22, 135-146.	4.1	21
212	A role for proteinase-activated receptorâ€“1 in inflammatory bowel diseases. Journal of Clinical Investigation, 2004, 114, 1444-1456.	8.2	82
213	Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. Anticancer Research, 2004, 24, 1255-60.	1.1	20
214	Proteinase-activated receptors (PARs) and immune function. Drug Development Research, 2003, 60, 65-70.	2.9	4
215	Relative contribution of acetylated cyclooxygenase (COX)â€2 and 5â€lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB Journal, 2003, 17, 1171-1173.	0.5	63
216	Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. British Journal of Pharmacology, 2003, 139, 1351-1359.	5.4	50

#	Article	IF	Citations
217	NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. Journal of Hepatology, 2003, 39, 932-939.	3.7	77
218	Endothelial nitric oxide synthase: the Cinderella of inflammation?. Trends in Pharmacological Sciences, 2003, 24, 91-95.	8.7	167
219	A magic bullet for mucosal protectionâ€¦and aspirin is the trigger!. Trends in Pharmacological Sciences, 2003, 24, 323-326.	8.7	58
220	Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10937-10941.	7.1	118
221	Inhibition of Intestinal Bacterial Translocation with Rifaximin Modulates Lamina propria Monocytic Cells Reactivity and Protects against Inflammation in a Rodent Model of Colitis. Digestion, 2002, 66, 246-256.	2.3	88
222	NCXâ€4016, a nitric oxideâ€releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. FASEB Journal, 2002, 16, 1645-1647.	0.5	41
223	Nonlinear partial differential equations and applications: NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15770-15775.	7.1	72
224	NCX-4016 (NO-Aspirin) Inhibits Lipopolysaccharide-Induced Tissue Factor Expression In Vivo. Circulation, 2002, 106, 3120-3125.	1.6	49
225	6Î±-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity. Journal of Medicinal Chemistry, 2002, 45, 3569-3572.	6.4	677
226	Importance of Innate Immunity and Collagen Binding Integrin Î±1Î²1 in TNBS-Induced Colitis. Immunity, 2002, 17, 769-780.	14.3	112
227	Role of PAR2 in pain and inflammation. Trends in Pharmacological Sciences, 2002, 23, 153-155.	8.7	46
228	Potential cardioprotective actions of no-releasing aspirin. Nature Reviews Drug Discovery, 2002, 1, 375-382.	46.4	129
229	Nitric Oxide???Releasing NSAIDs. Drug Safety, 2001, 24, 801-811.	3.2	74
230	Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? 1 1Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; COX, cyclooxygenase; LT, leukotriene; 5-LOX, 5-lipoxygenase; PG, prostaglandin; DFU, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsuphonyl)-phenyl-2(5H)-furanone; and DFP, diisopropyl fluorophosphate.. Biochemical Pharmacology, 2001, 62, 1433-1438.	4.4	264
231	Salicylates Inhibit T Cell Adhesion on Endothelium Under Nonstatic Conditions: Induction of L-Selectin Shedding by a Tyrosine Kinase-Dependent Mechanism. Journal of Immunology, 2001, 166, 832-840.	0.8	18
232	Galectin-1 exerts immunomodulatory and protective effects on concanavalin a-induced hepatitis in mice. Hepatology, 2000, 31, 399-406.	7.3	148
233	NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. British Journal of Pharmacology, 2000, 130, 1399-1405.	5.4	80
234	21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. British Journal of Pharmacology, 2000, 131, 1345-1354.	5.4	56

#	Article	IF	Citations
235	Anti-Very Late Antigen-1 Monoclonal Antibody Modulates the Development of Secondary Lesion and T-Cell Response in Experimental Arthritis. Laboratory Investigation, 2000, 80, 73-80.	3.7	33
236	IL-1Î² Converting Enzyme Is a Target for Nitric Oxide-Releasing Aspirin: New Insights in the Antiinflammatory Mechanism of Nitric Oxide-Releasing Nonsteroidal Antiinflammatory Drugs. Journal of Immunology, 2000, 165, 5245-5254.	0.8	101
237	Involvement of CD44 variant isoforms in hyaluronate adhesion by human activated T cells. European Journal of Immunology, 1995, 25, 2932-2939.	2.9	67
238	Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated withHelicobacter pylori infection and high levels of serum pepsinogens. Digestive Diseases and Sciences, 1995, 40, 2074-2080.	2.3	55
239	l-Arginine/nitric oxide pathway modulates gastric motility and gallbladder emptying induced by erythromycin and liquid meal in humans. Digestive Diseases and Sciences, 1995, 40, 1365-1371.	2.3	18
240	Abscess formation in hepatocellular carcinoma: Complications of percutaneous ultrasound-guided ethanol injection. Journal of Clinical Ultrasound, 1993, 21, 531-533.	0.8	14
241	5-Hydroxytryptamine 3-receptor antagonist modulates gallbladder emptying and motilin release induced by erythromycin. Digestive Diseases and Sciences, 1993, 38, 2236-2240.	2.3	17
242	Effect of erythromycin on gallbladder emptying in diabetic patients with and without autonomic neuropathy and high levels of motilin. Digestive Diseases and Sciences, 1992, 37, 1671-1677.	2.3	31
243	Erythromycin stimulates gallbladder emptying and motilin release by atropine-sensitive pathways. Digestive Diseases and Sciences, 1992, 37, 1678-1684.	2.3	39
244	Placebo-controlled comparison of piroxicam-?-cyclodextrin, piroxicam, and indomethacin on gastric potential difference and mucosal injury in humans. Digestive Diseases and Sciences, 1992, 37, 1825-1832.	2.3	16
245	Control of gastric pH with ranitidine in critically Ill patients. Digestive Diseases and Sciences, 1991, 36, 583-587.	2.3	13
246	Neurohumoral control of gallbladder motility in healthy subjects and diabetic patients with or without autonomic neuropathy. Digestive Diseases and Sciences, 1990, 35, 1089-1097.	2.3	41
247	Duodenal osmolality drives gallbladder emptying in humans. Digestive Diseases and Sciences, 1990, 35, 698-704.	2.3	10
248	Type III procollagen peptide and PZ-peptidase serum levels in pre-cirrhotic liver diseases. Clinica Chimica Acta, 1985, 148, 87-95.	1.1	16